Cargando…

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer

The prognosis of epithelial ovarian cancer (EOC), the primary cause of death from gynaecological malignancies, has only modestly improved over the last decades. Immunotherapeutic treatment using a cocktail of antigens has been proposed as a “universal” vaccine strategy. We determined the expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermeij, Renee, Daemen, Toos, de Bock, Geertruida H., de Graeff, Pauline, Leffers, Ninke, Lambeck, Annechien, ten Hoor, Klaske A., Hollema, Harry, van der Zee, Ate G. J., Nijman, Hans W.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946591/ https://www.ncbi.nlm.nih.gov/pubmed/20885926 http://dx.doi.org/10.1155/2010/891505

Ejemplares similares

Immunologic aspect of ovarian cancer and p53 as tumor antigen
por: Nijman, HW, et al.
Publicado: (2005)

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
por: Leffers, N, et al.
Publicado: (2010)

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
por: Komdeur, Fenne L., et al.
Publicado: (2016)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer
por: Komdeur, Fenne L., et al.
Publicado: (2017)

The role of ATM and 53BP1 as predictive markers in cervical cancer
por: Roossink, Frank, et al.
Publicado: (2012)

Reply: The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer
por: de Graeff, P, et al.
Publicado: (2007)

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies
por: de Graeff, P, et al.
Publicado: (2006)

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies
por: Vermeij, R., et al.
Publicado: (2011)

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
por: de Graeff, P, et al.
Publicado: (2008)

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
por: Draghiciu, Oana, et al.
Publicado: (2015)

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
por: Gooden, M J M, et al.
Publicado: (2011)

From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors
por: Draghiciu, Oana, et al.
Publicado: (2011)

Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome
por: Brunekreeft, Kim L., et al.
Publicado: (2020)

Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes
por: Ip, Peng Peng, et al.
Publicado: (2015)

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
por: Stelloo, Ellen, et al.
Publicado: (2016)

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
por: Draghiciu, Oana, et al.
Publicado: (2015)

Pain evaluation during gynaecological surveillance in women with Lynch syndrome
por: Helder-Woolderink, Jorien, et al.
Publicado: (2016)

Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens
por: van de Wall, Stephanie, et al.
Publicado: (2018)

Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement
por: Koopman, Timco, et al.
Publicado: (2018)

What is the added value of digital image analysis of HER2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms
por: Koopman, Timco, et al.
Publicado: (2019)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer
por: Crijns, Anne P. G, et al.
Publicado: (2009)

A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development
por: Draghiciu, Oana, et al.
Publicado: (2015)

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer
por: Wouters, MCA, et al.
Publicado: (2015)

An Overview of Innovative Techniques to Improve Cervical Cancer Screening
por: Nijhuis, Esther R., et al.
Publicado: (2006)

Feasibility of endometrial sampling by vaginal tampons in women with Lynch syndrome
por: Woolderink, Jorien M., et al.
Publicado: (2020)

Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7
por: van de Wall, Stephanie, et al.
Publicado: (2015)

Association of homozygous variants of STING1 with outcome in human cervical cancer
por: Lubbers, Joyce M., et al.
Publicado: (2020)

Therapeutic Vaccines and Cancer Immunotherapy
por: Bhatt, Darshak, et al.
Publicado: (2020)

Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.
por: van der Zee, A. G., et al.
Publicado: (1992)

Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival
por: Corvigno, Sara, et al.
Publicado: (2016)

Association of Promoter Methylation of VGF and PGP9.5 with Ovarian Cancer Progression
por: Brait, Mariana, et al.
Publicado: (2013)

Correction: Association of Promoter Methylation of VGF and PGP9.5 with Ovarian Cancer Progression
por: Brait, Mariana, et al.
Publicado: (2013)

Correction: Association of Promoter Methylation of VGF and PGP9.5 with Ovarian Cancer Progression
por: Brait, Mariana, et al.
Publicado: (2013)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis
por: Bhatt, Darshak K., et al.
Publicado: (2021)

The combined signatures of hypoxia and cellular landscape provides a prognostic and therapeutic biomarker in hepatitis B virus‐related hepatocellular carcinoma
por: Chen, Shipeng, et al.
Publicado: (2022)

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands
por: Westra, Tjalke A, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_775j8lo7kc126ma1bmmetqb9j0